DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and twelve approved drugs.

There are sixty-seven US patents protecting TEVA drugs. There are forty-three tentative approvals on TEVA drugs.

There are seven hundred and eighty-nine patent family members on TEVA drugs in forty-six countries and five hundred and forty-four supplementary protection certificates in fourteen countries.

Summary for Teva

International Patents:	789
US Patents:	67
Tradenames:	471
Ingredients:	414
NDAs:	712
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074142-002	Dec 21, 1993		DISCN	No	No
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-003	Jan 17, 2017		DISCN	Yes	No	9,572,803		Y
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017		RX	Yes	No	9,731,087		Y
Teva	FLUVOXAMINE MALEATE	fluvoxamine maleate	TABLET;ORAL	075893-001	Sep 10, 2002	AB	RX	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-001	May 16, 2006	5,532,415
Teva Branded Pharm	MIRCETTE	desogestrel; ethinyl estradiol	TABLET;ORAL-28	020713-001	Apr 22, 1998	4,921,843
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000	5,766,573
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000	6,352,684

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1.25 mg		2008-11-03
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Tablets	0.5 mg and 1 mg		2010-05-17
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Delayed-release Tablets	20 mg		2015-06-03
	Tablets	0.625 mg		2009-03-02
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.3 mg, 0.45 mg and 0.9 mg		2009-03-19
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	for Injection	3.5 mg/vial		2016-10-26

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

Non-Orange Book US Patents for Teva

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,459,445	Estrogenic compounds and topical pharmaceutical formulations of the same
7,619,117	Rasagiline formulations and processes for their preparation
7,598,420	Rasagiline formulations and processes for their preparation
8,338,396	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

International Patents for Teva Drugs

Country	Document Number	Estimated Expiration
Portugal	1699434
Japan	5931972
Canada	2883641
Ukraine	88186

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
90018-6	Sweden		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
C0037	France		PRODUCT NAME: OLMESARTAN MEDOXOMIL; NAT. REGISTRATION NO/DATE: NL28292 20030806; FIRST REGISTRATION: DE - 50202.00 20020813
/2001	Austria		PRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm